Evidence has accumulated over the last decade that exposure to mite allergens plays a critical role in the development of nasal and bronchial hyperreactivity (1, 2) . The therapy of perennial rhinitis includes various preventive measures and pharmacologic treatment with or without immunotherapy. Effective elimination of mite allergen seems to be dif®cult, and even when partial reduction of allergen exposure can be achieved, allergic symptoms may not be affected (3, 4) . Immunotherapy by subcutaneous injection of increasing doses of allergens has been part of allergy treatment for 80 years. It has been demonstrated to be a clinically effective treatment for allergic disorders such as rhinoconjunctivitis (5, 6) or asthma (7, 8) . As this route of application is inconvenient and occasionally associated with severe systemic adverse effects (9) , several trials have been conducted with local (noninjected) allergen-speci®c immunotherapy by either oral, sublingual, nasal, or bronchial routes. However, the results have been contradictory and the European Academy of Allergology and Clinical Immunology (EAACI) proposed recommendations in 1993 to improve safety and demonstrate greater ef®cacy (10) . Seven well-designed studies demonstrated the clinical effectiveness of sublingual-swallow immunotherapy (SLIT) with grass (11±13), Parietaria (14) , olive pollen (15) , and mite allergens (16, 17) . In the light of these data, a recent WHO position paper (18) stated that SLIT may be a viable alternative to parenteral injection therapy for treating allergic airways diseases, but further studies are needed to de®ne the indications and therapeutic target dose of this form of immunotherapy.
This study was designed to evaluate the safety and ef®cacy of SLIT in patients with perennial rhinitis caused by house-dust mite.
Material and methods

Patients
Seventy-®ve patients (mean age: 26.4t12 years; range: 6±51 years) with a history of perennial rhinitis with or without asthma agreed to take part in this clinical trial. Careful evaluation of clinical history clearly indicated the role of exposure to domestic house-dust mites as the major trigger of the symptoms. Patients also experienced symptoms not suf®ciently controlled by antihistamines or topical medications. IgE-mediated rhinitis was demonstrated in all patients selected by positive skin prick tests to Dermatophagoides pteronyssinus (D.pt.) and D. farinae (D.f.) standardized extract (Stallerge Ánes SA, Antony, France) and speci®c IgE (D.pt. and D.f.) positivity (RASTiclass 2). Nineteen patients had positive skin tests to one or several other inhalant allergens (cat, dog, Alternaria, cockroach, ®ve-grass pollens mix [orchard, meadow, ryegrass, sweet vernal, and timothy], Artemisia pollen, ragweed pollen, and birch pollen), but none of these skin sensitivities were associated with evidence of clinical sensitization. Patients sensitized to cat or dog allergen and living with pets at home were not included in the study. None of the patients had previously received immunotherapy with D.pt., none used oral or inhaled steroids, and none had any other signi®cant illness. The study protocol was approved by the ethics committee of the Pellegrin Children's Hospital, Bordeaux, France, and patients, or both parents of minors, signed informed consent forms before starting the study.
Allergen preparation
The standardized extract used throughout the study was the same batch of equal proportions of a mixture of D.pt. and D.f. (Stallerge Ánes SA, Antony, France). The extract was graded into four concentrations: 1, 10, 100, and 300 IR/ml. The in-house reference extract (labeled 100 IR [index of reactivity] is de®ned as the concentration eliciting by skin prick test a geometric mean wheal size of 7 mm diameter in 30 subjects sensitive to the corresponding allergen. The Der p 1 and Der f 1 contents of 1 ml of the 100 IR allergen extract used in this study were 4.8 and 3.7 mg, respectively.
Immunotherapy
Patient selection was not followed by a run-in observation period. Subjects were randomized to receive either a D.pt./D.f. preparation in 50% aqueous glycerol or placebo. The placebo preparation was identical to active treatment in terms of composition, appearance, presentation, taste, and color, but obviously did not contain allergens. The duration of treatment was 24 months, and treatment was initiated between November 1994 and January 1995. The study was completed in January 1997. During a 4-week incremental dose period, patients took daily increasing doses from 1±10 drops of the 1-IR/ml vial from day 1 to day 4, then 1±10 drops of the 10-IR/ml vial from day 5 to day 8, then 1±20 drops of the 100-IR/ml vial from day 9 to day 15, and ®nally 5±20 drops of the 300-IR/ml vial during the next 2 weeks. The highest dose (20 drops from the 300-IR/ml vial) was administered daily for 4 weeks, and then 3 days per week throughout the maintenance phase. Each dose had to be taken in the morning before breakfast, and drops of allergen had to be kept under the tongue for at least 2 min before swallowing. According to this schedule, an average cumulative dose of 90 000 IR (equivalent to 2.2 mg of Der p 1 and 1.7 mg of Der f 1) of allergens was administered to each patient undergoing active treatment, at the end of the trial.
Skin reactivity
Before treatment, after 12 months, and at the end of the trial, quantitative skin prick tests were performed with a Stallerpoint H device, with ®ve serial threefold dilutions of D.pt. and D.f. extracts (300, 100, 30, 10, and 1 IR/ml, Stallerge Ánes SA). The wheals were marked after 15 min with a thin pen and then transferred onto a transparent adhesive tape.
Symptom and medication diary
Patients (or their parents) were instructed to keep a diary during the treatment period, for weekly evaluation of symptoms according to a 4-point scoring system (0: no symptoms; 3: severe symptoms) for each nasal symptom (sneezing, nasal discharge, itching, and nasal obstruction). The maximal cumulated clinical score per patient was 12. Although some patients had ocular symptoms associated with rhinitis, only nasal symptoms were evaluated for analysis of ef®cacy. When necessary, patients were allowed to use the following drugs: antihistamine (cetirizine 10-mg tablets), intranasal corticosteroid (¯unisolide), and betamethasone 0.5-mg tablets. Other medications, such as long-lasting antihistamines, cromones, and parenteral corticosteroids, were not permitted during the study. The patients had to record on the same diary card whenever they used medications, and a speci®c weekly score was assigned (1 point: one puff of nasal¯unisolide per nostril, 2 points: one cetirizine tablet, 3 points: one betamethasone tablet). This assigned score was established not on the basis of the strength of each drug, but rather on the frequency of use, as, in this study, nasal corticosteroids were allowed to be used more frequently than antihistamines as ®rst-line treatment.
Patients were also asked to assess subjectively their symptoms according to a 4-point scoring system (1: totally improved, 2: partially improved, 3: unchanged, and 4: worsened) and on a 100-mm visual analog scale (VAS) (from 0 mm [no improvement] to 100 mm [remarkable improvement]. The physicians also expressed their opinion of each patient's clinical status (1: totally improved, 2: partially improved, 3: unchanged, and 4: worse).
Immunologic parameters D.pt.-and D.f.-speci®c IgE and IgG4 were determined at the end of the trial by commercial kits, according to the manufacturer's instructions (CAP System EIA method, Pharmacia AB, Uppsala, Sweden), on serum samples taken at the beginning of the study, and after 12 and 24 months. IgE values were expressed as kU/l, and IgG4 values were expressed as a percentage of a reference serum standard.
Exposure to house-dust mite
Patients were asked to vacuum-clean their bedroom and mattresses on enrolment in the study, and then at 12 and 24 months. They had to use their own vacuum cleaner at a constant vacuuming time of 2 min/m 2 . Dust samples were stored at 4uC in sealed vacuum paper bags until analysis. Samples were processed without sieving. The concentration of house-dust mite was determined by a semiquantitative guanine assay (Acarex Test H ) (Allergopharma, Reinbek, Germany). Results were expressed on a 4-point scale: 0: guanine content of <0.6 mg/g of dust, 1: 0.6±2.5 mg/g, 2: 2.5±10 mg/g, and 3: >10 mg/g (19) . Before starting treatment, all patients were asked not to use speci®c measures to avoid housedust mites during the study, in order to maintain the same level of exposure to house-dust mites.
Statistical analysis
Qualitative data were analyzed by the chi-square test or Fisher's exact test. Symptoms, medication intake, skin tests, and IgE and IgG4 speci®c to house-dust mite were analyzed statistically by nonparametric tests; the Wilcoxon rank sum test was used for intragroup analysis, and the Mann±Whitney U-test for intergroup analysis. All tests were two-tailed, and the level of signi®cance was set at 0.05.
Results
Seventy-®ve patients were included in this study. Seventy-two patients were available for intent-to-treat analysis (36 in the active group and 36 in the placebo group). Three patients were excluded from the intentto-treat analysis due to missing data for the primary end point. Twenty-seven patients dropped out of the study during the ®rst year, and another six patients dropped out during the second year (Fig. 1) . The number of dropouts was signi®cantly greater in the placebo group than in the active group (22 patients and 11 patients, respectively; P<0.01). The number of patients who dropped out because of lack of ef®cacy was eight out of 37 (21.6%) in the active treatment group compared to 15 out of 38 (39.5%) in the placebo group (chisquare=2.81, P=0.09). Other reasons for discontinuing immunotherapy were poor compliance and loss to follow-up for nine patients (three in the active group; six in the placebo group) and other diseases for four patients (one in the active group; three in the placebo group).
The baseline clinical and demographic characteristics of the 72 patients eligible for analysis (Table 1) did not reveal any signi®cant differences between the active treatment and placebo groups except for mean age and D.f.-speci®c IgE levels.
Exposure to house-dust mite
The results were available for 68 patients on inclusion and showed that 47 out of 68 patients (70%) had class 2±3 guanine levels in their mattress samples. The guanine levels were not signi®cantly different between the active and placebo groups ( Table 2) . After 24 months, the number of patients with class 2±3 guanine levels decreased signi®cantly in both groups (P=0.01), while there was a concomitant increase in the number of patients with low guanine levels (class 1), indicating a marked change of indoor allergen load.
Symptom scores
The patients' clinical status was assessed 1 month after starting treatment due to the lack of run-in period to assess the baseline clinical score. Symptom scores were not signi®cantly different between the two groups 1 month after starting treatment (Table 3) . A statistically signi®cant decrease in weekly nasal symptom scores, except for nasal itching, was observed in both groups after 12 months of treatment (P<0.05). The total symptom score decreased by 31% in the active group and 17% in the placebo group, with no signi®cant difference between the two groups. After 24 months, all symptoms had decreased signi®cantly (P<0.05) in the active and placebo groups, except for the nasal itching score in the placebo group. When compared to the 1-month score, the total symptom score was reduced by 40% in the active group and 20% in the placebo group, but the between-group difference was not signi®cant. As indicated in Fig. 2 , for the 42 patients who completed the trial, the total symptom scores decreased in a similar way in the two groups over the entire treatment period, and the difference was not signi®cant. Nor did the patients' and physicians' subjective assessments by VAS or the 0±4 scale reveal any signi®cant difference between active treatment or placebo (data not shown).
Medication scores
After 12 and 24 months of treatment, the score of nasal corticosteroid and H 1 -antihistamine intake was signi®-cantly reduced in the active group, while only the nasal Figure 2 . Mean (tSEM) total nasal symptom scores in active treatment (n=24) and placebo (n=18) groups of patients who completed trial. corticosteroid score was signi®cantly reduced in the placebo group (Table 4 ). The total medication score decreased signi®cantly after 12 (P<0.05) and 24 months (P<0.05) of treatment in both groups, and the between-group difference was not signi®cant. A cumulative symptoms plus medication (Table 5 ) score was calculated and showed a signi®cant decrease after 12 and 24 months of treatment in the active group (50% reduction) and placebo group (35% reduction), but no signi®cant differences between the two groups.
Skin reactivity
No signi®cant decrease of wheal areas obtained by prick test with D.pt. was observed for either active treatment or placebo groups (data not shown).
Immunologic parameters
As indicated in Table 6 , for the 42 patients who completed the trial, speci®c D.pt. and D.f. IgE levels increased signi®cantly after 12 months of treatment in the active treatment group (P<0.05), but remained unchanged in the placebo group. After 24 months, speci®c IgE decreased slightly in the active group, while the IgE levels in the placebo group were lower than those obtained at enrolment.
Speci®c IgG4 did not change signi®cantly in either the active group or the placebo group at any of the follow-up investigations (Table 6) .
Safety assessment
Two patients receiving active treatment reported local adverse reactions (mouth itching and burning). In the placebo group, one patient reported an episode of mild asthma, and another one had an episode of rhinosinusitis. No severe adverse effects were reported or detected.
Discussion
This study compared house-dust-mite SLIT and placebo, administered for 24 months, for perennial allergic rhinitis. One feature of this study is the large number of patients who dropped out, a factor which decreased the power of the analysis. However, it should be stressed that the fact that a large number of patients dropped out because of lack of ef®cacy in the placebo group indicates a trend toward better compliance in the active treatment group due to the ef®cacy of immunotherapy. A signi®cant reduction of nasal symptoms and medication scores was observed in the active and placebo groups.
According to the criteria de®ned by Malling (20) , the ef®cacy of immunotherapy in double-blind, placebocontrolled trials must be supported by an improvement of symptom/medication scores by more than 30%, and this was the case in both groups of this study with no signi®cant differences. The clinical ef®cacy of immunotherapy in rhinitis caused by house-dust mite has been insuf®ciently documented, and only two studies, performed by subcutaneous injections, satis®ed these criteria (21, 22) . The failure to demonstrate a signi®cant difference between the immunotherapy group and the placebo group in our study was probably due to the insuf®cient doses administered to the patients. SLIT trials performed in rhinitis caused by house-dust mite have reported discordant results. In a previous study, Tari et al. (16) demonstrated clinical improvement of nasal and bronchial reactivity after 18 months of SLIT in patients with rhinitis and asthma. However, the authors did not indicate the cumulative dose of major allergen Der p 1 administered to the patients. In another study using a chemically modi®ed allergen (allergoid) of house-dust mite, Passalacqua et al. (17) showed a signi®cant reduction in nasal symptom scores in the immunotherapy group compared to the placebo group after 24 months of treatment. As stated by the authors, modi®cation of the allergen into an allergoid prevented determination of the level of Der p 1 in the allergen extract. On the other hand, in a double-blind, placebo-controlled study performed in 30 dust-miteallergic children, Hirsch et al. (23) did not observe any consistent clinical bene®t in actively treated patients receiving a mean cumulative dose of 0.57 mg of Der p 1. In a recent double-blind controlled study, Bousquet et al. (24) treated asthmatic patients sublingually with housedust mites for 24 months with a mean cumulative dose of 4.2 mg of Der p 1 (twice the cumulative dose used in our study) and showed a signi®cant improvement of rhinitis symptoms, FEV 1 , and peak expiratory¯ow. The most important feature in our study is the role of the reduction in domestic allergen load observed at 12 and 24 months in both groups, an observation which probably indicates that patients took avoidance measures during the study despite our recommendations. This reduction had a marked impact on modulation of symptom/medication scores and introduced a possible bias in the evaluation of ef®cacy. This explanation is supported by the reduction of mite-speci®c IgE observed in the placebo group, probably due to changes in allergen exposure. Sensi et al. (25) reported a signi®cant reduction in nasal and serum speci®c IgE after 3 months of avoidance of mite allergen.
Concerning safety, no life-threatening adverse event was observed in this study, and the adverse effect rate was very low compared to the data reported in other SLIT studies using allergens of house-dust mite (16±18) or pollen (11±16).
In conclusion, this study showed that SLIT with house-dust-mite extract in perennial allergic rhinitis was well tolerated. In terms of ef®cacy, the lack of signi®cant clinical improvement in the active group compared to the placebo group was probably due to the effect of the reduction of allergen load due to avoidance measures which interfered with precise evaluation of the effect of SLIT.
